Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03432286 · ClinicalTrials.gov registry record · Phase 3

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

A Phase 3 study of Episodic Migraine, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
533
Enrollment target
20
Study locations

NCT03432286 is a Phase 3 study of Episodic Migraine that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 533 participants, above the 456-participant average among 13 other Episodic Migraine trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03432286, a Phase 3 study of Episodic Migraine, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
533 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

Conditions Studied

Episodic Migraine

Interventions

  • DRUG Placebo
  • DRUG Galcanezumab

Study Locations (20)

Florida

  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
  • University of Miami Don Suffer Clinical Research Building - Miami
  • Ezy Medical Research - Miami Lakes
  • Clinical Neuroscience Solutions - Orlando
  • Avanza Medical Research Center - Pensacola
  • USF Health - Tampa
  • Premiere Research Institute at Palm Beach Neurology - West Palm Beach

Arizona

  • 21st Century Neurology, a Division of Xenoscience, Inc. - Phoenix
  • Phoenix Children's Hospital - Phoenix
  • Center for Neurosciences - Tucson

Idaho

  • Medical Research Partners - Ammon
  • Elite Clinical Trials - Blackfoot
  • Northwest Clinical Trials - Boise

California

  • Miller Children's & Women's Hospital Long Beach - Long Beach
  • Wr-McCr, Llc - San Diego

Georgia

  • Clinical Integrative Research Center of Atlanta, LLC - Atlanta
  • Meridian Clinical Research, LLC - Savannah

Alabama

  • Rehabilitation & Neurological Services - Huntsville

Colorado

  • Children's Hospital Colorado - Aurora

Illinois

  • Inpatient Pharmacy - Hoffman Estates

Trial Details

FieldValue
Enrollment Target 533 participants
Start Date 2018-03-14
Est. Completion 2026-11
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03432286

The ClinicalTrials.gov registry entry for NCT03432286 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 533 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 456-participant average among 13 other Episodic Migraine trials with a reported enrollment target (17% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03432286 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Arizona, Idaho.

Frequently Asked Questions

What is clinical trial NCT03432286 about?

NCT03432286 is a clinical study titled "A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine". The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine he...

What is the current status of trial NCT03432286?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2018-03-14. Estimated completion is 2026-11.

What conditions does trial NCT03432286 study?

This clinical trial studies the following conditions: Episodic Migraine.

What interventions are being tested in trial NCT03432286?

The interventions under investigation include: Placebo (DRUG), Galcanezumab (DRUG).

Who is sponsoring clinical trial NCT03432286?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03432286 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Episodic Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Episodic Migraine

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.